Verseon has acquired Edammo, an artificial intelligence-focused company, to deepen its own AI-based drug discovery platform. Financial terms were not disclosed.
https://www.pharmalive.com/wp-content/uploads/2022/09/BioSpacemergerdeal9-30-2022.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-10-18 09:22:552022-10-18 09:22:55Verseon acquires Edammo to deepen drug discovery approach